Skip to main content
πŸ«„GASTROENTEROLOGY

Inflammatory Bowel Disease

Crohn's, ulcerative colitis, celiac β€” from symptom suppression to microbiome repair and mucosal healing

~7 million people worldwide live with IBD; ~1 in 100 has celiac disease; hundreds of millions have functional GI disorders.
IN HUMAN TRIALS
75/ 100
TO BROAD CURE

MILESTONERELi VE UCCD Phase 2b reported positive results for duvakitug (anti-TL1A) in Crohn’s and UC.

LATESTNo new duvakitug major efficacy/regulatory update beyond improvements was reported.

Disease-modifying therapies are in human clinical trials Β· Not medical advice.

CURRENT STATUS

Gastroenterology has moved from symptom control to targeted mucosal healing. A wave of selective biologics and oral small molecules β€” anti-IL-23 antibodies (risankizumab, mirikizumab), JAK inhibitors and S1P modulators β€” now drives a meaningful share of IBD patients to endoscopic remission, not merely symptomatic relief. A first-in-class anti-TL1A antibody paired with a predictive genetic biomarker is in late-stage trials, intestinal microbiota transplant protocols are being standardized for ulcerative colitis and recurrent C. difficile, and AI endoscopic scoring now grades mucosal healing at expert level to standardize trial endpoints. Fecal calprotectin and CRP give objective, fast readouts of gut inflammation, and celiac-specific tolerance and enzyme therapies are entering trials.

KEY BREAKTHROUGHS

Risankizumab (Skyrizi) & mirikizumab (Omvoh) β€” IL-23 inhibitors driving endoscopic remission in Crohn's and ulcerative colitis

TL1A antibodies (e.g., tulisokibart) β€” first-in-class pathway showing strong Phase 2 IBD results with a predictive genetic biomarker

Intestinal Microbiota Transplant (IMT) protocols being standardized for ulcerative colitis and recurrent C. difficile

AI endoscopic scoring systems now grade mucosal healing at expert level, standardizing trial endpoints

AI-COMPRESSED PIPELINE

AI TOOLS ACCELERATING CURES

Microbiome Sequencing AIEndoscopic Deep-Learning ScoringMulti-omics Response PredictionNanoparticle Gene Delivery Design

KEY ORGANIZATIONS

AbbVieEli LillyTakedaJohnson & JohnsonSeres / Microbiome consortia

KEY CLINICAL TRIALS

TL1A Antibody (Tulisokibart / PRA023) in Ulcerative Colitis & Crohn's

View

Merck (Prometheus Biosciences)

A first-in-class anti-TL1A antibody paired with a companion genetic test that predicts responders. Targets a newly validated inflammatory pathway with the goal of deeper, more durable remission than existing biologics.

πŸ‘₯ Phase 2/3 programs across UC and Crohn's diseaseπŸ“ US, EU β€” multicenter

Intestinal Microbiota Transplant for Ulcerative Colitis

View

Academic microbiome consortia (multi-site)

Standardized donor-derived microbiota transplant, sometimes paired with diet conditioning, aiming to reset a dysbiotic gut microbiome and induce remission in ulcerative colitis without immunosuppression.

πŸ‘₯ Recruiting β€” randomized vs. placebo/standard careπŸ“ US, Australia, EU β€” academic centers

TIMELINE ESTIMATE

Deep endoscopic remission (biologics / oral small molecules): available now for many. Broad microbiome-based cures: 3–6 years. Celiac tolerance therapy: 4–8 years.

EXPLORE FULL CURE PROTOCOL